Catalog No.
DHC05701
Expression system
Mammalian Cells
Species reactivity
Human
Isotype
Human lysosomal acid glucosylceramidase
Target
SGTase, Cholesterol glucosyltransferase, GBA, Cholesteryl-beta-glucosidase, D-glucosyl-N-acylsphingosine glucohydrolase, GLUC, Imiglucerase, Beta-glucocerebrosidase, Lysosomal acid GCase, Beta-GC, Alglucerase, GC, Lysosomal acid glucosylceramidase, Acid beta-glucosidase
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P04062
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
CAS: 2725857-55-4
Clone ID
Velaglucerase Beta
Safety analysis of self-administered enzyme replacement therapy using data from the Fabry Outcome and Gaucher Outcome Surveys., PMID:40155993
Evaluation of Lyso-Gb1 as a biomarker for Gaucher disease treatment outcomes using data from the Gaucher Outcome Survey., PMID:39881421
Osteonecrosis in Gaucher disease in the era of multiple therapies: Biomarker set for risk stratification from a tertiary referral center., PMID:37249220
An observational study to investigate the relationship between plasma glucosylsphingosine (lyso-Gb1) concentration and treatment outcomes of patients with Gaucher disease in Japan., PMID:36329499
Long-term safety and effectiveness of velaglucerase alfa in Gaucher disease: 6-year interim analysis of a post-marketing surveillance in Japan., PMID:34863216
Impact of Long-Term Enzyme Replacement Therapy on Glucosylsphingosine (Lyso-Gb1) Values in Patients with Type 1 Gaucher Disease: Statistical Models for Comparing Three Enzymatic Formulations., PMID:34299318
Imino- and Azasugar Protonation Inside Human Acid β-Glucosidase, the Enzyme that is Defective in Gaucher Disease., PMID:32191378
A novel mutation causing type 1 Gaucher disease found in a Japanese patient with gastric cancer: A case report., PMID:29979419
Spotlight on taliglucerase alfa in the treatment of pediatric patients with type 1 Gaucher disease., PMID:29388611
Lysosomal storage diseases., PMID:29152458
Reductions in glucosylsphingosine (lyso-Gb1) in treatment-naïve and previously treated patients receiving velaglucerase alfa for type 1 Gaucher disease: Data from phase 3 clinical trials., PMID:28851512
Effect of velaglucerase alfa enzyme replacement therapy on red blood cell properties in Gaucher disease., PMID:28621801
Treatment-naïve Gaucher disease patients achieve therapeutic goals and normalization with velaglucerase alfa by 4years in phase 3 trials., PMID:27839979
Stability is maintained in adults with Gaucher disease type 1 switched from velaglucerase alfa to eliglustat or imiglucerase: A sub-analysis of the eliglustat ENCORE trial., PMID:27722092
Enzyme Replacement or Substrate Reduction? A Review of Gaucher Disease Treatment Options., PMID:27559188
Seven-year safety and efficacy with velaglucerase alfa for treatment-naïve adult patients with type 1 Gaucher disease., PMID:25903392
Enzymes approved for human therapy: indications, mechanisms and adverse effects., PMID:25648140
Taliglucerase alfa: an enzyme replacement therapy using plant cell expression technology., PMID:24630271
Glycosylation and functionality of recombinant β-glucocerebrosidase from various production systems., PMID:23980545
Safety and efficacy of velaglucerase alfa replacement therapy for patients with type 1 Gaucher disease., PMID:30736148
[Guidelines for type 1 Gaucher's disease]., PMID:22230128
[Molecular basis of treatment in Gaucher's disease]., PMID:22230123
Gaucher's disease: the changing paradigm of a lysosomal disorder., PMID:22230118
Velaglucerase alfa: a new option for Gaucher disease treatment., PMID:22013559
Velaglucerase alfa in the treatment of Gaucher disease type 1., PMID:21927713
Recent advances in treatment approaches to Gaucher disease., PMID:21235447
Gaucher disease: clinical profile and therapeutic developments., PMID:21209725
Comparative therapeutic effects of velaglucerase alfa and imiglucerase in a Gaucher disease mouse model., PMID:20505772
Phase 1/2 and extension study of velaglucerase alfa replacement therapy in adults with type 1 Gaucher disease: 48-month experience., PMID:20299511
Characterization of gene-activated human acid-beta-glucosidase: crystal structure, glycan composition, and internalization into macrophages., PMID:19741058
For research use only. Not for human or drug use.
